Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38-Reference-Cited by-同舟云学术

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Published:2019-02-13 Issue:5 Volume:83 Page:993-998
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Iwase Mariko,Fujita Ken-ichi,Nishimura Yuki,Seba Natsumi,Masuo Yusuke,Ishida Hiroo,Kato Yukio,Kiuchi Yuji

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-019-03784-8/fulltext.html

Reference19 articles.

1. Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A (2018) Drug review: pazopanib. Jpn J Clin Oncol 48:503–513

2. Spigel DR, Burris HA 3rd, Greco FA, Shih KC, Gian VG, Lipman AJ, Daniel DB, Waterhouse DM, Finney L, Heymach JV, Hainsworth JD (2018) Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: a randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer 124:2355–2364

3. Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP (2015) A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Investig New Drugs 33:138–147

4. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V (2017) Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7:15963

5. Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG (2018) Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemother Pharmacol 82:353–360

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review;Therapeutic Drug Monitoring;2024-04-30

2. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer;Frontiers in Pharmacology;2024-01-30

3. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance;Pharmacology & Therapeutics;2023-08

4. Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins;Chemico-Biological Interactions;2022-12

5. Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation;European Journal of Drug Metabolism and Pharmacokinetics;2022-02-11